Showing results (1-10 of 7) with videos related to
Sort By:
Pageof 1
Environmental Science & Technology|July 3, 2009
Learning in times of change: a dynamic explanation for technological progressF Ferioli, B C C van der ZwaanJournal of Thrombosis and Haemostasis : JTH|March 8, 2005
Does activated protein C-resistant factor V contribute to thrombin generation in hemophilic plasma?M H A Bos, D W E Meijerman, C van der Zwaan, et al.Netherlands Heart Journal : Monthly Journal of the Netherlands Society of Cardiology and the Netherlands Heart Foundation|February 20, 2015
Adolescent with occluded left main coronary arteryR Wieman, D Beelen, C van der Zwaan, et al.Journal of Thrombosis and Haemostasis : JTH|July 1, 2014
Identification of N-linked glycosylation and putative O-fucosylation, C-mannosylation sites in plasma derived ADAMTS13N Sorvillo, P H Kaijen, M Matsumoto, et al.British Journal of Haematology|March 1, 1997
Heparin-induced thrombocytopenia and thrombosis: a prospective analysis of the incidence in patients with heart and cerebrovascular diseasesM C Kappers-Klunne, D M Boon, W C Hop, et al.The New England Journal of Medicine|May 4, 2000
Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of Oral Xemilofiban in Controlling Thrombotic EventsW W O'Neill, P Serruys, M Knudtson, et al.Heart (British Cardiac Society)|March 17, 2001
Pharmacodynamics and safety of lefradafiban, an oral platelet glycoprotein IIb/IIIa receptor antagonist, in patients with stable coronary artery disease undergoing elective angioplastyK M Akkerhuis, M J van Den Brand, C van Der Zwaan, et al.Pageof 1